Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifapentine

FDA-approved product (tablet, oral), marketed as Priftin, Rifapentine.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifapentine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB05; FDA class Rifamycin Antimycobacterial

Repurposing investigation

Rifapentine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • E. coli76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis95.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rifapentine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifapentine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)

    NCT03435146 · start 2018-01-18

    Registered record
    Registry ID
    NCT03435146
    Conditions
    Respiratory Tract Infections; HIV Infections
    Interventions
    3HP plus DTG +2NRTIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-01-18
    Completion
    2022-12-07
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Infections; HIV Infections
    Intervention3HP plus DTG +2NRTIs
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

    NCT03089983 · start 2017-08-21

    Registered record
    Registry ID
    NCT03089983
    Conditions
    Opioid Dependence; Addiction; HIV/AIDS; Tuberculosis; Hepatitis
    Interventions
    Isoniazid; Rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-08-21
    Completion
    2024-04-04
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Dependence; Addiction; HIV/AIDS; Tuberculosis +1 more
    InterventionIsoniazid; Rifapentine
    PhaseNot applicable
    Registry statusCompleted

  • Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

    NCT02651259 · start 2017-03-13

    Registered record
    Registry ID
    NCT02651259
    Conditions
    Tuberculosis
    Interventions
    Rifapentine (RPT); Isoniazid (INH); Pyridoxine (vitamin B6)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-03-13
    Completion
    2019-04-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine (RPT); Isoniazid (INH); Pyridoxine (vitamin B6)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • The Correlate of Risk Targeted Intervention Study

    NCT02735590 · start 2016-09-20

    Registered record
    Registry ID
    NCT02735590
    Conditions
    Tuberculosis
    Interventions
    Isoniazid; Rifapentine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-09-20
    Completion
    2019-12-31
    Enrolment
    2,927

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid; Rifapentine
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers

    NCT02771249 · start 2016-06-03

    Registered record
    Registry ID
    NCT02771249
    Conditions
    HIV Infected Population With Latent Tuberculosis
    Interventions
    rifapentene (RPT); darunavir/cobicistat (DRV/c); Isoniazid (INH); Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06-03
    Completion
    2021-08-17
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infected Population With Latent Tuberculosis
    Interventionrifapentene (RPT); darunavir/cobicistat (DRV/c); Isoniazid (INH); Pyridoxine
    PhasePhase 1
    Registry statusCompleted

  • VDOT for Monitoring Adherence to LTBI Treatment

    NCT02641106 · start 2016-03-08

    Registered record
    Registry ID
    NCT02641106
    Conditions
    Tuberculosis; Latent Tuberculosis Infection
    Interventions
    Video Directly Observed Therapy; In-Person DOT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-03-08
    Completion
    2020-06-30
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Latent Tuberculosis Infection
    InterventionVideo Directly Observed Therapy; In-Person DOT
    PhaseNot applicable
    Registry statusCompleted

  • TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

    NCT02410772 · start 2016-01-25

    Registered record
    Registry ID
    NCT02410772
    Conditions
    Tuberculosis
    Interventions
    rifapentine; rifapentine and moxifloxacin; control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-05
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine; rifapentine and moxifloxacin; control
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

    NCT02563327 · start 2016-01-25

    Registered record
    Registry ID
    NCT02563327
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Moxifloxacin; Rifampin; Isoniazid; Pyrazinamide; Ethambutol; Pyridoxine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-08-30
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Moxifloxacin; Rifampin; Isoniazid +3 more
    PhasePhase 3
    Registry statusCompleted

  • Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan

    NCT02208427 · start 2014-08

    Registered record
    Registry ID
    NCT02208427
    Conditions
    Latent Tuberculosis Infection
    Interventions
    Rifapentine and Isoniazid for 3 months; Isoniazid for 9 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-08
    Completion
    2016-12
    Enrolment
    283

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis Infection
    InterventionRifapentine and Isoniazid for 3 months; Isoniazid for 9 months
    PhasePhase 3
    Registry statusUnknown

  • Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

    NCT01690403 · start 2012-12

    Registered record
    Registry ID
    NCT01690403
    Conditions
    Tuberculosis
    Interventions
    rifapentine (M000473); EFZ EMT TDF
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-12
    Completion
    2014-03
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine (M000473); EFZ EMT TDF
    PhasePhase 1
    Registry statusCompleted

  • Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults

    NCT01574638 · start 2012-06

    Registered record
    Registry ID
    NCT01574638
    Conditions
    Tuberculosis
    Interventions
    Rifapentine (RPT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-06
    Completion
    2013-06
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine (RPT)
    PhasePhase 1
    Registry statusCompleted

  • Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

    NCT01404312 · start 2012-05-23

    Registered record
    Registry ID
    NCT01404312
    Conditions
    Tuberculosis; HIV Infections
    Interventions
    Rifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05-23
    Completion
    2017-11-14
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV Infections
    InterventionRifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)
    PhasePhase 3
    Registry statusCompleted

  • PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

    NCT02216331 · start 2010-03

    Registered record
    Registry ID
    NCT02216331
    Conditions
    Tuberculosis
    Interventions
    TMC207; rifapentine; rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2010-05
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionTMC207; rifapentine; rifampicin
    PhasePhase 1
    Registry statusCompleted

  • Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

    NCT00728507 · start 2009-11

    Registered record
    Registry ID
    NCT00728507
    Conditions
    Tuberculosis
    Interventions
    Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-11
    Completion
    2013-04
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    PhasePhase 2
    Registry statusTerminated

  • TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

    NCT00694629 · start 2008-12

    Registered record
    Registry ID
    NCT00694629
    Conditions
    Pulmonary Tuberculosis
    Interventions
    rifapentine; rifapentine 10 mg/kg; rifapentine 15 mg/kg; rifapentine 20 mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12
    Completion
    2013-12
    Enrolment
    334

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    Interventionrifapentine; rifapentine 10 mg/kg; rifapentine 15 mg/kg; rifapentine 20 mg/kg
    PhasePhase 2
    Registry statusCompleted